Psoriasis was less likely to progress to psoriatic arthritis (PsA) among patients treated with interleukin-17 (IL-17) or ...

Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced ...

It was better than Stelara in reaching ... impacting the lives of psoriasis patients,” he added. BE VIVID will follow patients for a year after starting treatment, so additional readouts will ...

If it reaches the market, JNJ-2113 could extend J&J's psoriasis franchise, currently represented by injectable IL-12 and IL-23 inhibitor Stelara ... daily icotrokinra treatment aligned with ...

A real-world study in Spain finds faster improvements with induction therapy but highlights long-term drug survival ...

Scalp psoriasis improvement was maintained with long-term tildrakizumab treatment in what researchers said is the first ...

Roflumilast demonstrated effectiveness and safety in treating psoriasis, with added benefits for patients with comorbidities.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.In the second of a three-part ...

Super Bowl LIX champion Dallas Goedert of the Philadelphia Eagles shares his journey with plaque psoriasis. After 20 years of ...